Vermillion Posts 6 Percent Rise in Q2 Revenues, Halts OVA2 Development | GenomeWeb

This story originally ran on Aug. 16.

Vermillion this week reported $321,000 in revenues for the second quarter of 2012, up 6 percent from $304,000 in same period last year.

The rise was driven by an increase in sales of the company's OVA1 ovarian cancer diagnostic. Test volume for OVA1 was 4,150 during the quarter, up 6 percent compared to Q2 2011 and in line with the company's forecast.

Vermillion's license revenues, collected through its agreement with Quest Diagnostics, were flat year over year at $113,000.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.